# Intense Monitoring Study on Tyvyt

> **NCT04237233** · — · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Relapsed or Refractory Classical Hodgkin's Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04237233
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-02
- **Primary completion:** 2023-06
- **Final completion:** 2023-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237233, "Intense Monitoring Study on Tyvyt". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04237233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*